Sodium ozagrel is an antiplatelet drug administered for acute ischemic stroke. It is eliminated predominantly into the urine and may enhance the antiplatelet effect in patients with renal insufficiency or in patients who are elderly. However, few studies have investigated its use in such patients. Here, we evaluated the effects of sodium ozagrel on the antiplatelet effect in patients with renal insufficiency. The antiplatelet effect was retrospectively determined from the laboratory data of 23

more »

... atients receiving sodium ozagrel during the period March 2008 to April 2013. In patients who were not taking aspirin, the adenosine 5′ -diphosphate disodium salt (ADP)-induced platelet aggregation threshold index (PATI) and the collagen-induced PATI were respectively 1 μM/mL and 0.7 μg/mL higher in those with renal insuf ciency than in those with normal renal function. However, in patients who were taking aspirin, the ADP-induced PATI and the collagen-induced PATI were respectively 0.1 μM/mL lower and 0.2 μg/mL higher in those with renal insuf ciency than in those with normal renal function.These ndings indicate that sodium ozagrel enhances the antiplatelet effect in renal insuf ciency. When administering it to patients with renal insuf ciency, physicians should carefully monitor for adverse effects such as digestive hemorrhage and hemorrhagic stroke.